Log in

Relevant bibliographies by topics / Dexketoprofeno / Journal articles

To see the other types of publications on this topic, follow the link: Dexketoprofeno.

Journal articles on the topic 'Dexketoprofeno'

Author: Grafiati

Published: 4 June 2021

Last updated: 3 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Dexketoprofeno.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

González-Pérez, R., I. Trébol, I. García-Ríos, M. A. Arregui, and R. Soloeta-Arechavala. "Fotodermatitis de contacto por dexketoprofeno. Descripción de dos casos." Actas Dermo-Sifiliográficas 97, no. 7 (2006): 456–59. http://dx.doi.org/10.1016/s0001-7310(06)73440-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Vera, P., L. Zapata, I. Gich, J. Mancebo, and A. J. Betbesé. "Efectos hemodinámicos y antipiréticos del paracetamol, metamizol y dexketoprofeno en pacientes críticos." Medicina Intensiva 36, no. 9 (2012): 619–25. http://dx.doi.org/10.1016/j.medin.2012.02.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

García Ramiro, M., L. Alonso Guardo, A. Matilla Álvarez, R. Bartol Sevillano, L. M. Vaquero Roncero, and C. Muriel Villoria. "Eficacia de la asociación paracetamol-metamizol vs. paracetamol-dexketoprofeno en manejo de dolor agudo postoperatorio." Revista de la Sociedad Española del Dolor 20, no. 6 (2013): 279–84. http://dx.doi.org/10.4321/s1134-80462013000600001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Yucel, Evren, Iclal Ozdemir Kol, Cevdet Duger, Kenan Kaygusuz, Sinan Gursoy, and Caner Mimaroglu. "Bloqueo de los Nervios Ilioinguinal e Ilio-hipogástrico con Dexketoprofeno Intravenoso Mejora la Analgesia después de la Histerectomía Abdominal." Brazilian Journal of Anesthesiology (Edicion en Espanol) 63, no. 4 (2013): 334–39. http://dx.doi.org/10.1016/j.bjanes.2012.07.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Rubio-González, B., and F. J. Ortiz-de Frutos. "Eczema alérgico de contacto a aldehído hexil cinámico, aldehído cinámico y 3,4 metilbencilideno alcanfor en un paciente con dermatitis fotoalérgica de contacto previa a dexketoprofeno." Actas Dermo-Sifiliográficas 106, no. 2 (2015): 146–48. http://dx.doi.org/10.1016/j.ad.2014.06.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

&NA;. "Dexketoprofen." Reactions Weekly &NA;, no. 1201 (2008): 15–16. http://dx.doi.org/10.2165/00128415-200812010-00042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

&NA;. "Dexketoprofen." Reactions Weekly &NA;, no. 1049 (2005): 7. http://dx.doi.org/10.2165/00128415-200510490-00022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

&NA;. "Dexketoprofen." Reactions Weekly &NA;, no. 1297 (2010): 21. http://dx.doi.org/10.2165/00128415-201012970-00060.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Miranda, Hugo F., Viviana Noriega, Fernando Sierralta, Ramón Sotomayor-Zárate, and Juan Carlos Prieto. "The Antinociceptive Activities of Certain NSAIDS Combinations in Murine Orofacial Test." Drug Research 70, no. 09 (2020): 424–28. http://dx.doi.org/10.1055/a-1217-6777.

Full text

Abstract:

AbstractPain models are mostly in rodents and between them formalin orofacial test allow discrimination among antinociception and anti-inflammation. This assay use a formalin solution injected into the upper right lip of each mouse which produces two periods of pain separated by an inactive period. The aims of the present study were to evaluate, by means of the isobolographic analysis, the antinociception and anti-inflammatory activities of the following NSAIDs: dexketoprofen, diclofenac, piroxicam and metamizole in an orofacial. The NSAIDs administered intraperitoneally produced a dose-dependent activity with the following order of potency of the rubbing behavior, in phase I: diclofenac>dexketoprofen>piroxicam>metamizole and in the phase II: metamizole>diclofenac>piroxicam>dexketoprofen. The coadministration of NSAIDs resulted in a synergistic interaction, which according to the value of the potency of the combination (II) presents the following range: dexketoprofen plus metamizole>dexketoprofen plus diclofenac>dexketoprofen plus piroxicam, in phase I and dexketoprofen plus metamizole>dexketoprofen plus piroxicam>dexketoprofen plus diclofenac, on the phase II. Data obtained in this work corroborate that NSAIDs alone or in combination inducing activities by additional mechanism of action supplementary to inhibition of COXs. This fact represent a novel approach that could be used as multimodal management of orofacial pain, since with this treatment strategies, by the reduction of doses, can help to diminish side effects of other dugs such opioids.

APA, Harvard, Vancouver, ISO, and other styles

10

Mititelu-Tartau, Liliana, Maria Bogdan, Daniela Angelica Pricop, et al. "Biocompatibility and Pharmacological Effects of Innovative Systems for Prolonged Drug Release Containing Dexketoprofen in Rats." Polymers 13, no. 7 (2021): 1010. http://dx.doi.org/10.3390/polym13071010.

Full text

Abstract:

The present study reports on the in vivo biocompatibility investigation and evaluation of the effects of liposomes containing dexketoprofen in somatic sensitivity in rats. Method: The liposomes were prepared by entrapping dexketoprofen in vesicular systems stabilized with chitosan. The in vivo biocompatibility was evaluated after oral administration in white Wistar rats: Group I (DW): distilled water 0.3 mL/100 g body weight; Group II (DEX): dexketoprofen 10 mg/kg body weight (kbw); Group III (nano-DEX): liposomes containing dexketoprofen 10 mg/kbw. Blood samples were collected from caudal lateral vein one day and seven days after the substance administration, to assess the eventual hematological, biochemical, and immunological changes. The investigation of somatic pain reactivity was performed using the hot plate test, to count the latency time response evoked by the thermal paws’ noxious stimulation. Results: Original liposomes entrapping dexketoprofen, with mean size of 680 nm and good stability, were designed. Laboratory analysis indicated no substantial variances between the three treated groups. The treatment with liposomes containing dexketoprofen resulted in a prolongation of the latency time response, statistically significant in the interval between 90 min and 10 h, in the hot plate test. Conclusions: The use of liposomes with dexketoprofen proved a good in vivo biocompatibility in rats and prolonged analgesic effects in the hot plate test.

APA, Harvard, Vancouver, ISO, and other styles

11

María Fernanda Maya Guerrero, Fabiola María Nuccio Giordano, Bernardo José Gutiérrez Sougarret, and Alejandro Díaz Girón Gidi. "Pre-emptive analgesia VS Prophylactic analgesia and its influence on postoperative pain in postoperative laparoscopic cholecystectomy patients." International Journal of Science and Research Archive 1, no. 2 (2020): 038–43. http://dx.doi.org/10.30574/ijsra.2020.1.2.0029.

Full text

Abstract:

Introduction: There are no studies on the use of dexketoprofen for postoperative pain control in patients undergoing laparoscopic cholecystectomy. Purpose: To assess if the timing of dexketoprofen administration influences the intensity of postoperative pain in patients undergoing laparoscopic cholecystectomy. Materials and methods used: Experimental, longitudinal, double-blind, randomized study. 50 mg of dexketoprofen diluted in 50 ml of 0.9% saline was administered to 50 patients divided into two groups: Pre-operative group: the substance was administered one hour before the beginning of surgery. Trans-operative group: the substance was administered at the moment when the gallbladder was separated from the liver base. The Numerical Pain Scale was evaluated and the number of doses and the total dose of tramadol that the patients received as analgesic rescue was quantified. Results: Administration of dexketoprofen before starting laparoscopic cholecystectomy tends to reduce the intensity of postoperative pain without being statistically significant. Conclusion: The timing of dexketoprofen administration has no impact on postoperative pain in patients operated for laparoscopic cholecystectomy.

APA, Harvard, Vancouver, ISO, and other styles

12

Omelchenko, M. Yu. "Non-steroidal anti-inflammatory drugs in practice of cardiologist: choice of drug." Medical alphabet, no. 28 (November 18, 2020): 22–26. http://dx.doi.org/10.33667/2078-5631-2020-28-22-26.

Full text

Abstract:

Data from an original study evaluating the efficacy and safety of dexketoprofen in the conservative treatment of pain syndrome in patients are presented. This paper presents three clinical cases of successful conservative treatment of pain in patients. Patients, depending on the therapy they received, were divided into three groups: patient S., 50 years old, (pain in the joints) received Dexketoprofen-SZ at a dose of 25 mg twice a day for 5 days; a patient, 50 years old, (severe pain in the lumbosacral spine) received Dexketoprofen-SZ 25 mg every 8 hours (daily dose not more than 75 mg) for 5 days; the patient, 20 years old, (painful heavy periods) received Dexketoprofen-SZ, depending on the intensity of pain, 25 mg every 8 hours. Conclusions. The drug Dexketoprofen-SZ at a dosage of 25 mg 2–3 times a day has shown high efficacy and good tolerability in various patients in the practice of an outpatient cardiologist.

APA, Harvard, Vancouver, ISO, and other styles

13

Gromova, O. A., V. I. Demidov, A. G. Kalacheva, I. Yu Torshin, T. R. Grishina, and T. E. Bogacheva. "Investigation of the anticonvulsant and remyelinating potential of dexketoprofen on a rat model of primary generalized seizures." Neurology, Neuropsychiatry, Psychosomatics 12, no. 4 (2020): 84–90. http://dx.doi.org/10.14412/2074-2711-2020-4-84-90.

Full text

Abstract:

Objective: to investigate the effect of dexketoprofen on the severity of seizures on a rat model of primary generalized seizures caused by thiosemicarbazide; to evaluate the neuroprotective effect of the drug.Material and methods. The investigation was conducted on 72 male albino rats weighing 200–300 g. The animals were given dexketoprofen and/or comparison drugs (gabapentin, sodium valproate) for 5 days, after which the seizure model was reproduced. The effects of the drugs were evaluated from a set of neurological tests and the results of a histopathological examination of the brain.Results and discussion. Dexketoprofen reduced the severity, duration, and number of primary generalized seizures and potentiated the anticonvulsant effects of gabapentin and sodium valproate. Histopathological and morphometric examinations of the rat brain showed that dexketoprofen inhibited the formation of irreversible neuronal changes (27.2%; control, 55.7%), by transferring them into reversible changes (47.7%; control, 21.8%).Conclusion. The investigation made it possible to conclude that dexketoprofen had a moderate neuroprotective effect neurologically and morphometrically verified.

APA, Harvard, Vancouver, ISO, and other styles

14

Khranovska, N., O. Skachkova, R. Sydor, and L. Skivka. "The effect of analgesia with omnopon and dexketoprofen on the endocytic activity of phagocytes of different localization on the surgical tumor resection model." Bulletin of Taras Shevchenko National University of Kyiv. Series: Problems of Physiological Functions Regulation 20, no. 1 (2016): 69–73. http://dx.doi.org/10.17721/2616_6410.2016.20.69-73.

Full text

Abstract:

We aimed to compare the effect of anesthesia with opioid analgesics omnopon and non-selective COX-2 inhibitor dexketoprofen on the endocytic activity of phagocytes of different localization sites on the model of surgical tumor removal. The study used 50 C57/black mice, which were transplanted with Lewis lung carcinoma in the hind paw pad. After 22 days the tumor paw was amputated. Analgesics (omnopon 10 mg/kg, dexketoprofen – 20 mg/kg) was administered 30 minutes before the operation and once per day for 3 days after surgery. Assessment of endocytic activity of phagocytes was performed by flow cytometry before the surgery, at days 1 and 3 after the surgery. It was found that dexketoprofen analgesia maintain the endocytic activity of blood and spleen phagocytes in the postoperative period. At day 3 postsurgery in dexketoprofen- treated animals phagocytic activities of blood and spleen granulocytes were higher compared to the group receiving opioid analgesia by 70% and 86% respectively. Phagocytic indices of blood and spleen monocytes were also 2 times higher at dexketoprofen-treated mice. Thus, dexketoprofen analgesia maintains the activity of blood and spleen phagocytes in mice after the surgical tumor removal at a much higher level as compared with the omnopon analgesia.

APA, Harvard, Vancouver, ISO, and other styles

15

Ustun, Yasemin Burcu, Ersin Koksal, Cengiz Kaya, et al. "The Effects of Dexketoprofen on Endogenous Leptin and Lipid Peroxidation During Liver Ischemia Reperfusion Injury." International Surgery 99, no. 6 (2014): 757–63. http://dx.doi.org/10.9738/intsurg-d-14-00121.1.

Full text

Abstract:

Abstract Hepatic ischemia reperfusion (IR) injury has complex mechanisms. We investigated the effect of dexketoprofen on endogenous leptin and malondialdehyde (MDA) levels. Wistar albino rats were divided into 4 equal groups and were subjected to 1-hour ischemia and different subsequent reperfusion intervals. Dexketoprofen was administered in a dose of 25 mg/kg 15 minutes before ischemia induction and 1-hour reperfusion to the Dexketoprofen one-hour reperfusion group, n = 6 (DIR1) group and 6-hour reperfusion to the Dexketoprofen six-hour reperfusion group, n = 6 (DIR6) group. In the control groups, 0.9% physiologic serum (SF) was administered 15 minutes before ischemia induction and 1-hour reperfusion to the one-hour reperfusion group, n = 6 (IR1) group and 6-hour reperfusion to the six-hour reperfusion group, n = 6 (IR6) group. Although serum leptin (P = 0.044) and hepatic tissue MDA levels (P = 0.004) were significantly higher in the IR6 group than in the IR1 group, there were no significant differences in dexketoprofen pretreatment between the DIR1 and DIR6 groups. There were no differences in serum MDA levels among the 4 groups, and serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities were significantly higher in the IR1 (P = 0.026 and P = 0.018, respectively) and IR6 (P = 0.000 and P = 0.002, respectively) groups than in the DIR1 and DIR6 groups. Dexketoprofen pretreatment can protect the liver from IR injury by decreasing inflammation and lipid peroxidation. Our study shows that dexketoprofen has no effects on endogenous leptin during IR injury.

APA, Harvard, Vancouver, ISO, and other styles

16

&NA;. "Dexketoprofen trometamol." Reactions Weekly &NA;, no. 1111 (2006): 11. http://dx.doi.org/10.2165/00128415-200611110-00034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Dexketoprofen trometamol." Reactions Weekly &NA;, no. 944 (2003): 7. http://dx.doi.org/10.2165/00128415-200309440-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Dexketoprofen trometamol." Reactions Weekly &NA;, no. 979 (2003): 10. http://dx.doi.org/10.2165/00128415-200309790-00029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

&NA;. "Dexketoprofen/ketoprofen." Reactions Weekly &NA;, no. 1184 (2008): 16. http://dx.doi.org/10.2165/00128415-200811840-00047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

&NA;. "Dexketoprofen trometamol." Reactions Weekly &NA;, no. 1192 (2008): 15. http://dx.doi.org/10.2165/00128415-200811920-00040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Mauleón, D. "Dexketoprofen Trometamol." Drugs of the Future 21, no. 6 (1996): 587. http://dx.doi.org/10.1358/dof.1996.021.06.356766.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Jamdade, P. T., A. Porwal, J. V. Shinde, et al. "Efficacy and Tolerability of Intramuscular Dexketoprofen in Postoperative Pain Management following Hernia Repair Surgery." Anesthesiology Research and Practice 2011 (2011): 1–4. http://dx.doi.org/10.1155/2011/579038.

Full text

Abstract:

Objective. To evaluate the safety and efficacy of intramuscular dexketoprofen for postoperative pain in patients undergoing hernia surgery.Methodology. Total 202 patients received single intramuscular injection of dexketoprofen 50 mg or diclofenac 50 mg postoperatively. The pain intensity (PI) was self-evaluated by patients on VAS at baseline 1, 2, 4, 6, and 8 hours. The efficacy parameters were number of responders, difference in PI (PID) at 8 hours, sum of analogue of pain intensity differences (SAPID), and onset and duration of analgesia. Tolerability assessment was done by global evaluation and adverse events in each group.Results. Dexketoprofen showed superior efficacy in terms of number of responders (P=.007), PID at 8 hours (P=.02), and SAPID0–8 hours(P<.0001). It also showed faster onset of action (42 minutes) and longer duration of action (6.5 hours). The adverse events were comparable in both groups.Conclusion. Single dose of dexketoprofen trometamol 50 mg given intramuscularly provided faster, better, and longer duration of analgesia in postoperative patients of hernia repair surgery than diclofenac 50 mg, with comparable safety.

APA, Harvard, Vancouver, ISO, and other styles

23

Luna-Bertos, Elvira De, Javier Ramos-Torrecillas, Francisco Javier Manzano-Moreno, Olga García-Martínez, and Concepción Ruiz. "Effects on Growth of Human Osteoblast-Like Cells of Three Nonsteroidal Anti-Inflammatory Drugs." Biological Research For Nursing 17, no. 1 (2014): 62–67. http://dx.doi.org/10.1177/1099800414527155.

Full text

Abstract:

Some nonsteroidal anti-inflammatory drugs (NSAIDs) have adverse effects on bone tissue. The objective of this study was to determine the effect of different doses of dexketoprofen, ketorolac, and metamizole on growth of the osteoblast MG63 cell line. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide spectrophotometry results showed that MG63 cell growth was significantly inhibited after 24 hr of culture with doses of 10, 20, 100, or 1,000 µM of each NSAID and with doses of 0.1, 1, or 5 µM of dexketoprofen and ketorolac but not metamizole. Cell-cycle studies revealed that dexketoprofen and ketorolac treatments significantly arrested the cell cycle in phase G0/G1, increasing the percentage of cells in this phase. Apoptosis/necrosis studies showed significant changes versus control cells, with an increased percentage of cells in apoptosis after treatment with 10, 100, or 1,000 µM of metamizole and after treatment with 1, 10, 100, or 1,000 µM of dexketoprofen or ketorolac. In conclusion, treatment of osteoblast-like cells with high doses of the NSAIDs tested increased not only the percentage of cells in apoptosis but also the percentage of necrotic cells.

APA, Harvard, Vancouver, ISO, and other styles

24

Dadasheva, M. N., G. I. Nurullina, and R. V. Gorenkov. "Cervicocranialgia: rationale for and evaluation of the clinical efficiency of therapy with the Russian generics of dexketoprofen and tolperisone." Neurology, Neuropsychiatry, Psychosomatics 11, no. 4 (2019): 94–99. http://dx.doi.org/10.14412/2074-2711-2019-4-94-99.

Full text

Abstract:

Objective: to comparatively evaluate the clinical efficiency of cervicocranialgia therapy with dexketoprofen (flamadex) and tolperisone (calmyrex), as well as with their combination. Patients and methods. The investigation enrolled 90 patients aged 30–60 years with cervicocranialgia, who were randomized into three equal groups. Group 1 included 7 men and 23 women who took dexketoprofen; Group 2 consisted of 13 men and 17 women who were prescribed dexketoprofen and tolperisone; Group 3 comprised 18 men and 12 women who used tolperisone. The three patient groups underwent assessment of the intensity of pain on a visual analogue scale and the degree of muscle tone on a 3-point scale and evaluation of the efficiency of therapy and the hemodynamic effect of the drugs in the common carotid and vertebral arteries. Results and discussion. In all the groups, their treatment reversed neck pain, headache, and dizziness, normalized muscle tone, and improved hemodynamics in the carotid and vertebral arteries. The effect was more pronounced in patients receiving combination treatment (Group 2). The therapy showed a high safety and a good tolerability. Conclusion. Dexketoprofen and tolperisone have been demonstrated to be effective and safe in treating cervicocranialgia.

APA, Harvard, Vancouver, ISO, and other styles

25

Gungor, Faruk, Kamil Can Akyol, Mustafa Kesapli, et al. "Intravenous dexketoprofen vs placebo for migraine attack in the emergency department: A randomized, placebo-controlled trial." Cephalalgia 36, no. 2 (2015): 179–84. http://dx.doi.org/10.1177/0333102415584604.

Full text

Abstract:

Objective Migraine is a leading headache etiology that frequently presents to the emergency department (ED). In the present study, we aimed to determine the efficacy of dexketoprofen in aborting migraine headaches in the ED. Methods This prospective, randomized, double-blind study was conducted in an ED of a tertiary care hospital using allocation concealment. Patients were allocated into two arms to receive the study drug; 50 mg dexketoprofen in 50 ml saline and 50 ml saline as placebo. Change in pain intensity was measured by the visual analog scale at baseline, both at 30 and 45 minutes after the study medication was administered. Rescue medication requirement and pain relapse were also recorded by a telephone follow-up at 48 hours. Results A total of 224 patients (112 in each group) were included into the final analysis. Mean age of the study participants was 37 ± 11 (SD) and 25% ( n = 56) of them were male. The median pain improvement at 45 minutes for patients receiving dexketoprofen was 55 (IQR: 49 to 60) and 30 (IQR: 25 to 35) for those receiving placebo. The mean difference between the two groups at 45 minutes was 21.4 (95% CI: 14.4. to 28.5). Rescue drugs were needed in 22.3% of patients who received dexketoprofen compared to 55.4% in patients who received placebo (dif: 33.1%; 95% CI: 20% to 45%). There were no adverse events reported in either group during the study period. Conclusion Intravenous dexketoprofen is superior to placebo in relieving migraine headaches in the ED. It may be a suitable therapy with minimum side effects in patients presenting with a migraine headache to the ED.

APA, Harvard, Vancouver, ISO, and other styles

26

Rossi, Patrizia, Paola Paoli, Stella Milazzo, et al. "A Combined Crystallographic and Computational Study on Dexketoprofen Trometamol Dihydrate Salt." Crystals 10, no. 8 (2020): 659. http://dx.doi.org/10.3390/cryst10080659.

Full text

Abstract:

Dexketoprofen trometamol is the tromethamine salt of dexketoprofen [(2S)-2-(3-benzoylphenyl)propanoic acid-2-amino-2-(hydroxymethyl)propane-1,3-diol], a nonsteroidal anti-inflammatory drug (NSAID) used for the treatment of moderate- to strong-intensity acute pain. The crystal structure of the hitherto sole known hydrate phase of dexketoprofen trometamol (DK-T_2H2O), as determined by single-crystal X-ray diffraction, is presented. The water molecules are arranged in dimers included in isolated sites and sandwiched between piles of trometamol cations. The molecular and crystal structures of DK-T_2H2O are analyzed and compared to those of the parent anhydrous crystal form DK-T_A. In both the crystal structures, all the potential H-bond donors and acceptor of the dexketoprofen and trometamol ions are engaged, and both the species crystallize in the P21 space group. However, during the DK-T_A➔DK-T_2H2O hydration process, the unique symmetry axis is not conserved, i.e., the ions are arranged in a different way with respect to the screw axis, even if the two crystal structures maintain structural blocks of DK anions and T cations. Quantum mechanical solid-state calculations provide some hints for the possible intermediate structure during the crystalline–crystalline hydration/dehydration process.

APA, Harvard, Vancouver, ISO, and other styles

27

Rossi, Patrizia, Paola Paoli, Andrea Ienco, Diletta Biagi, Maurizio Valleri, and Luca Conti. "A new crystal form of the NSAID dexketoprofen." Acta Crystallographica Section C Structural Chemistry 75, no. 6 (2019): 783–92. http://dx.doi.org/10.1107/s2053229619006533.

Full text

Abstract:

Dexketoprofen [(2S)-2-(3-benzoylphenyl)propanoic acid], C16H14O3, is the S-enantiomer of ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID) that has analgesic, antipyretic and anti-inflammatory properties, and finds applications for the short-term treatment of mild to moderate pain. A new crystalline phase of dexketoprofen is reported. Its solid-state structure was determined by single-crystal X-ray diffraction (SCXRD). The molecular structure of the two independent molecules found in the asymmetric unit of this new phase (DXKP-β) were compared to those of the already known crystal form of dexketoprofen (DXKP-α) and with the S-enantiomer of the racemic compound. The three different conformers of dexketoprofen found in DXKP-α and DXKP-β were then investigated by computational methods. The optimized structures are very close to the corresponding starting geometries and do not differ significantly in energy. The crystal packing of DXKP-β was studied by means of Hirshfeld surface (HS) analysis; interaction energies were also calculated. A comparison with DXKP-α shows close similarities between the two crystal forms, i.e. in both cases, molecules assemble through the catemer O—H...O synthon of the carboxylic acid stabilized by additional C—H...O contacts and, accordingly, the interaction energies, as well as the contributions to the HS area, are very similar. Finally, the thermal behaviour of the two polymorphs of dexketoprofen was assessed by means of XRD (both from single crystal and microcrystalline powder) and differential scanning calorimetry (DSC); both crystal forms are stable under the experimental conditions adopted (air, 300–350 K for DXKP-α and 300–340 K DXKP-β) and no solid–solid phase transition occurs between the two crystal forms in the investigated temperature range (from 100 K up to ca 350 K).

APA, Harvard, Vancouver, ISO, and other styles

28

Bayalieva, A. Zh, R. Ya Shpaner, and I. R. Ganeeva. "Comparative evaluation of the effectiveness of the transdermal therapeutic system with fentanil and gabapentine in head pain therapy." Regional Anesthesia and Acute Pain Management 13, no. 1-4 (2019): 5–9. http://dx.doi.org/10.17816/1993-6508-2019-13-1-4-5-9.

Full text

Abstract:

The study was conducted to comparatively evaluate the effectiveness a transdermal therapeutic system with fentanyl and gabapentin in the treatment of headache in patients with non-traumatic subarachnoid hemorrhage. When assessing the intensity of headache in patients, it was found that with severe pain immediately after endovascular occlusion, the use of transdermal fentanyl with dexketoprofen or paracetamol is most acceptable, and the combination of gabapentin with dexketoprofen / paracetamol is better in case of headache in a more delayed period.

APA, Harvard, Vancouver, ISO, and other styles

29

Barbanoj, Manuel-Jos??, Rosa-Mar??a Antonijoan, and Ignasi Gich. "Clinical Pharmacokinetics of Dexketoprofen." Clinical Pharmacokinetics 40, no. 4 (2001): 245–62. http://dx.doi.org/10.2165/00003088-200140040-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

&NA;. "Dexketoprofen launched in Spain." Inpharma Weekly &NA;, no. 1046 (1996): 22. http://dx.doi.org/10.2165/00128413-199610460-00047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Koroleva, I. A. "Dexketoprofen – an additional opportunity to control chronic pain syndrome in malignant neoplasms." Medical Council, no. 10 (June 24, 2019): 172–78. http://dx.doi.org/10.21518/2079-701x-2019-10-172-178.

Full text

Abstract:

Chronic pain syndrome (CPS) is an independent disease. Patients with disseminated malignant tumors may experience chronic pain even with successful anticancer therapy. For the control of CPS use the WHO analgesic ladder. Despite adequate pain relief, patients may experience breakthrough pain. Clinical guidelines suggest the use of opioids for the treatment of breakthrough pain. Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAIDs) of rapid action. The drug is highly effective for pain in the bones of various origins. Dexketoprofen can be used for incident predictable breakthrough pain.

APA, Harvard, Vancouver, ISO, and other styles

32

Josephine, Clara Valentia, Muhammad Ramli Ahmad, Hisbullah Hisbullah, and Abdul Wahab. "Perbandingan Intensitas Nyeri dan Kadar Prostaglandin Kombinasi Tramadol dan Deksketoprofen dengan Tramadol dan Parasetamol Intravena pada Pasien Bedah Ortopedi Ekstremitas Bawah." Jurnal Anestesi Perioperatif 7, no. 2 (2019): 75–82. http://dx.doi.org/10.15851/jap.v7n2.1691.

Full text

Abstract:

Analgesia multimodal adalah prinsip manajemen nyeri pascaoperasi. Penelitian ini merupakan uji klinis rancangan acak tersamar ganda. Tujuan penelitian ini membandingkan efek kombinasi analgesik tramadol dan deksketoprofen dengan tramadol dan parasetamol terhadap intensitas nyeri dan kadar prostaglandin (PGE2) di RSUP Dr. Wahidin Sudirohusodo serta Rumah Sakit Jejaring di Makassar pada bulan Juli–September 2018. Empat puluh enam pasien ASA PS I dan II yang menjalani operasi ortopedi ekstremitas bawah dibagi menjadi dua kelompok. Kelompok D adalah pasien yang menerima 50 mg tramadol dengan 50 mg deksketoprofen dan kelompok P adalah pasien yang menerima 50 mg tramadol dengan 1.000 mg parasetamol intravena. PGE2 dan intensitas nyeri dicatat selama penutupan kulit sebelum pemberian obat 8 dan 16 jam sesudahnya. Data dianalisis menggunakan Uji Mann-Whitney U dan paired t-test yang sesuai. Numeric rating scale (NRS) kelompok tramadol dan deksketoprofen lebih rendah dibanding dengan kelompok tramadol dan parasetamol dengan perbedaan bermakna (p<0,05). Kadar PGE2 menurun pada kelompok tramadol dan deksketoprofen (T1–T2 p=0,009 dan T0–T2 p=0,01), sedangkan kadar PGE2 pada kelompok tramadol dan parasetamol meningkat (T2–T1 p=0,227 dan T0–T2 p=0,706). Simpulan, kombinasi tramadol dan deksketoprofen mengurangi tingkat PGE2 dan intensitas nyeri dibanding dengan kombinasi tramadol dan parasetamol. Dexketoprofen Combination and Tramadol Paracetamol Combination in Lower Limb Orthopedic SurgeryMultimodal analgesia is one of the principles of postoperative pain management. This study aimed to compare the effect of analgesic combination of tramadol dexketoprofen and tramadol paracetamol on pain intensity and prostaglandin (PGE2) level. Forty-six ASA PS I and II patients undergoing lower limb orthopedic surgery were allocated into two groups. Group D received 50 mg tramadol with 50 mg dexketoprofen and group P received 50 mg tramadol with 1,000 mg paracetamol intravenously. The PGE2 and pain intensity were recorded during skin closure prior to drug administration, 8 and 16 hours afterwards. Data were analyzed as appropriate using Mann-Whitney U and paired t-test. The NRS of two groups were significantly different where the NRS of the Tramadol Dexketoprofen group was lower than that of the tramadol and paracetamol group (NRS T1 p=0.049, NRS T2 p=0.035). The PGE2 levels decreased in the tramadol dexketoprofen groups (T1–T2 p=0.009 and T0–T2 p=0.01), whereas PGE2 levels in tramadol paracetamol group increased (T2–T1 p=0.227 and T0–T2 p=0.706). In conclusion, tramadol dexketoprofen combination reduces the PGE2 level and pain intensity as opposed to tramadol paracetamol combination.

APA, Harvard, Vancouver, ISO, and other styles

33

Costea, D., V. Gherghina, R. Popescu, Gh Nicolae, Iulia Cîndea, and Alina Balcan. "The effect of dexketoprofen pre-emptively administered on the consumption of tramadol and the incidence of nausea and vomiting after laparoscopic cholecystectomy." ARS Medica Tomitana 20, no. 2 (2014): 91–96. http://dx.doi.org/10.2478/arsm-2014-0017.

Full text

Abstract:

Abstract The aim of our study has been to assess the comparative use of the two NSAIDs, dexketoprofen and ketoprofen, for postoperative analgesia after laparoscopic cholecystectomy mainly following: the quality of the analgesia, the incidence of potential adverse effects (for example, postoperative nausea and vomiting) and the rescue analgesics consumption (tramadol). This prospective, randomized, double-blind study included 90 patients undergoing laparoscopic cholecystectomy under general anaesthesia. Patients were randomly assigned into 2 groups: group D (n = 45) - patients that have received dexketoprofen 50 mg in dilution with10 ml saline solution iv., 30 minutes before the induction and group K (n = 45) - patients that have received ketoprofen 100 mg in dilution with 10 ml saline solution iv., 30 minutes before the induction (preemptive analgesia). Surgical interventions were conducted under general anaesthesia, with identical protocol for the two groups of study. Post-surgery analgesic regime consisting in 4 g of paracetamol administered for example in the first 24 hours, was started immediately after surgery. Boluses of tramadol of 100 mg (until 400 mg /daily) have been used as rescue analgesia. The main objectives of our study have been: post-surgery analgesia (VAS at mobilization, 0-100 mm) at 0, 2, 6, 12 and 24 hours after the surgery,the consumption of tramadol, incidence of PONV and the length of hospitalization period (LOS). Secondary objectives of the study have been: the incidence of gastrointestinal symptoms and the incidence of postsurgery blood losses. In the two study groups there have not been any differences concerning demographic data, post-surgery gastro-intestinal symptoms, postsurgery loss of blood and the hospitalization period. VAS was significantly lower in group D vs. K, at 0 and 6 hours after the surgery (p <0,05). The incidence of PONV was lower in the group of patients who received preemptive analgesia with dexketoprofen (p <0,05). The number of tramadol boluses administered and the number of patients requiring backup analgesia was lower in group D comparatively to group K. Preemptive administration of dexketoprofen seems to be more effective than the administration of ketoprofen for post-surgery multimodal analgesia after laparoscopic cholecystectomy. The preemptive administration of dexketoprofen also deereases tramadol consumption and the incidence of postoperative nausea and vomiting.

APA, Harvard, Vancouver, ISO, and other styles

34

Tok, Yağmur Pirinçci, Burcu Mesut, and Yıldız Özsoy. "Design, Preparation, and Evaluation of Taste-Masked Dexketoprofen of Orally Disintegrating Tablet by Using QbD Approach." Proceedings 78, no. 1 (2020): 30. http://dx.doi.org/10.3390/iecp2020-08675.

Full text

Abstract:

The present investigation was carried out to develop a taste-masked, orally disintegrating tablet containing Dexketoprofen for evaluating the effect of the coating amount on the product’s quality attributes via Quality by Design (QbD) systematical roadmap. Dexketoprofen, S(+)-enantiomer of bitter taste ketoprofen, involves an arylalkil group which is the most frequently used analgesic in the management of acute and chronic pain. To overcome of bitter-taste of the active pharmacological ingredients should apply a taste-masking approach. For this purpose, the bitter taste dexketoprofen particles were coated with a pH-dependent methacrylates polymer in which one of the method of taste-masking approaches. The experimental design was enforced with a four-factor, three-level Box–Behnken method within the framework of response surface modeling (RSM). A ready to use matrix excipient, Eudragit RS 30D, dextrates, aroma, and tablet pressing force were chosen as independent factors, and were assessed on four dependent factors: dissolution rate, disintegration time, tablet hardness, and friability %. Our findings indicate that when tablet pressing force is applied at 250 PSI, the tablets disintegrate within 1 minute, and the friability value is under 1%. Disintegration time increases as the coating amount increases. However, the Pareto charts shows engrossingly that the dissolution rate is affected mainly by tablet pressing force in first, third, and fifth time points, and by matrix excipient and coating in the 10th, 15th, 20th, and 30th time points. It was concluded that the QbD study helped to understand how the coating amount and process variables impacted the dissolution rate, disintegration time, tablet hardness, and friability % of the Dexketoprofen orally disintegrating tablet (ODT) finished product.

APA, Harvard, Vancouver, ISO, and other styles

35

Tok, Kenan Can, Mehmet Gumustas, Giorgi Jibuti, Halit Sinan Suzen, Sibel A. Ozkan, and Bezhan Chankvetadze. "The Effect of Enantiomer Elution Order on the Determination of Minor Enantiomeric Impurity in Ketoprofen and Enantiomeric Purity Evaluation of Commercially Available Dexketoprofen Formulations." Molecules 25, no. 24 (2020): 5865. http://dx.doi.org/10.3390/molecules25245865.

Full text

Abstract:

In a recent study, opposite enantiomer elution order was observed for ketoprofen enantiomers on two amylose-phenylcarbamate-based chiral columns with the same chemical composition of the chiral selector but in one case with coated while in the other with an immobilized chiral selector. In the present study, the influence of this uncommon effect on method validation parameters for the determination of minor enantiomeric impurity in dexketoprofen was studied. The validated methods with two alternative elution orders for enantiomers were applied for the evaluation of enantiomeric impurity in six marketed dexketoprofen formulations from various vendors. In most of these formulations except one the content of enantiomeric impurity exceeded 0.1% (w/w).

APA, Harvard, Vancouver, ISO, and other styles

36

&NA;. "Dexketoprofen trometamol prevents postoperative pain." Inpharma Weekly &NA;, no. 1342 (2002): 15. http://dx.doi.org/10.2165/00128413-200213420-00027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Pilipovich, A. A. "Dexketoprofen: therapeutic potential in neurology." Consilium Medicum 20, no. 9 (2018): 71–75. http://dx.doi.org/10.26442/2075-1753_2018.9.71-75.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Walczak, Jean-Sébastien. "Analgesic properties of dexketoprofen trometamol." Pain Management 1, no. 5 (2011): 409–16. http://dx.doi.org/10.2217/pmt.11.42.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Valenzuela, Nancy, Lluis Puig, María A. Barnadas, and Agustin Alomar. "Photocontact dermatitis due to dexketoprofen." Contact Dermatitis 47, no. 4 (2002): 237. http://dx.doi.org/10.1034/j.1600-0536.2002.470412.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Galindo, E. Cuerda, J. J. Goday Buján, J. Del Pozo Losada, J. García Silva, C. Peña Penabad, and E. Fonseca. "Photocontact dermatitis due to dexketoprofen." Contact Dermatitis 48, no. 5 (2003): 283–84. http://dx.doi.org/10.1034/j.1600-0536.2003.00114.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Shavlovskaya, O. A. "Dexketoprofen trometamol in dorsalgia treatment." Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 116, no. 9 (2016): 88. http://dx.doi.org/10.17116/jnevro20161169188-92.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Pchelintsev, M. V. "Pain syndrome in oncology. Possibilities of dexketoprofen administration." Meditsinskiy sovet = Medical Council, no. 9 (July 30, 2020): 146–54. http://dx.doi.org/10.21518/2079-701x-2020-9-146-154.

Full text

Abstract:

Pain is an important problem in oncology patients. Depending on its intensity, for pain treatment, analgesics of different pharmacological classes are used. According to WHO recommendations, for nociceptive pain treatment in oncology patients, non-steroidal antiinflammatory drugs (NSAIDs), mild and potent opioids are the essential medications. If in pain formation along with the nociceptive pain component, a neuropathic one is present, antiepilepsy drugs, tricyclic antidepressants, local anesthetics are added. Apart from these medicines, adjuvants are used. These agents potentiate the analgesic endpoint of NSAIDs and opioids, correct their adverse effects. Often, intensive pain development is driven by bone metastases, which form in oncologic processes of different primary localization. Herewith, patients could suffer from constant as well as from paroxysmal, “breakthrough” pain. The efficacy of NSAIDs in oncology patients is due not only to analgesic effect but also to their action on inflammatory processes in areas of tumor formation and growth as well as in metastatic foci. Dexketoprofen trometamol is an effective and safe NSAID, a water-soluble salt of a dexketoprofen dextrorotatory stereoisomer. The preparation has a good lipid and water solubility. Thus, dexketoprofen trometamol can rapidly absorb, create therapeutic concentrations in blood serum, and penetrate through brain-blood barrier. It produces a significant and fast analgesic action in different diseases, which is related both to central analgesic mechanisms and to anti-inflammatory effect in peripheral tissues. Dexketoprofen trometamol efficacy is proven in bone pain related to oncological disease. The availability of intravenous solution and the prompt action at oral administration allow using the medicine for “breakthrough” pain. The medication significantly potentiates the action of mild and potent opioids at combined therapy, which allows to use opioid analgesics in lower doses.

APA, Harvard, Vancouver, ISO, and other styles

43

Shoshmina, O. V., S. N. Gureyeva, and L. V. Vronska. "Study on the influence of excipients on pharmaco-technological properties of tablet cores of dexketoprofen." Farmatsevtychnyi zhurnal, no. 1 (March 18, 2019): 53–63. http://dx.doi.org/10.32352/0367-3057.1.19.05.

Full text

Abstract:

Among the group of nonsteroidal anti-inflammatory drugs, the active substance dexketoprofen trometamol is released. Its pharmacological and pharmacological and technological characteristics are induced in the article. The feasibility of using the wet granulation method in the development of tablets with dexketoprofen is substantiated. The purpose of this work was selecting the optimal excipients for obtaining a high-quality medicinal product. The excipients were selected and grouped into 4 functional groups. For the planning of the experiment, a matrix was based on the hyper-Greek-Latin parallelepiped. The tablets were prepared by wet granulation. The effect of the excipients for the granulate, tablet mass and core tablets was studied by such factors as loss on during of the granulate, bulk density of the tablet mass, resistance to crushing, friability, disintegration. The experimental data were subjected to statistical analysis by the method of dispersion analysis. The results were expressed using ranked rows of benefits and bar charts. The results of the study of the effect of excipients from groups of fillers, disintegrants, sliding, binding substances on the quality of granulate, tablet mass and tablet cores are provided. The results of the study show that the loss on drying is most influenced by fillers. The quality of the tablet mass depends more on the solution used for wetting, so the nature of the binder and the method of moistening have a determining effect on the bulk density of the tablet mass. Fillers have the most significant effect on the resistance to crushing of the core tablets. The hardness of the dexketoprofen tablet cores characterizes friability, the leading position on the influence is occupied by a group of disintegrants, namely: a mixture of sodium starch and corn starch. The most significant influence on disintegration is exerted by a binder and a moistening method. The generalized results of the study showed that leaders from the four groups of the excipients are appeared by the influence on the technological indicators of granulate, tablet mass and tablet cores. In the result of the work the excipients were selected for development of the composition of the tablet cores, their influence on the pharmaco- technological indicators was also investigated. The excipients were selected for further optimization of the composition of the tablets with dexketoprofen, namely: MCC 102, a mixture of sodium starch glycolate and corn starch, corn starch and the use of a 40% dexketoprofen trometamol.

APA, Harvard, Vancouver, ISO, and other styles

44

Skorobogatykh, K. V., and Yu E. Azimova. "Comparative evaluation of the efficiency of a sumatriptan/dexketoprofen combination versus sumatriptan monotherapy in the treatment of a migraine attack." Neurology, Neuropsychiatry, Psychosomatics 10, no. 3 (2018): 42–47. http://dx.doi.org/10.14412/2074-2711-2018-3-42-47.

Full text

Abstract:

Migraine is a chronic brain disease with a high prevalence and a marked deterioration in quality of life. Triptans are the gold standard for migraine attack therapy, but they are not effective in all patients. The aim of an observational program was to compare a sumatriptan/dexketoprofen combination and sumatriptan monotherapy for attack relief. Patients and methods. The observation program included 38 migraine patients. A migraine attack was relieved with a combination of sumatriptan 100 mg and dexketoprofen 25 mg in 20 patients and with only sumatriptan 100 mg in 18 patients (Group 2). All the study participants filled out a questionnaire in which they indicated the time of attack onset, the time of drug intake, the intensity of pain, and the presence of concomitant symptoms (nausea, phono-and photophobia) before and 0.5, 1, 2, 4, 8, and 24 hours after drug administration. The investigators estimated the key indicators of the observation program: pain relief at 2, 4, 8, and 24 hours and a significant decrease in pain intensity at 30 minutes, 1 and 2 hours. Therapy satisfaction was determined using the Patient Perception of Migraine Questionnaire (PPMQ) that the patients filled out at 24 hours after the attack. Results. A larger number of patients receiving combined therapy with sumatriptan 100 mg and dexketoprofen 25 mg noted a significant decrease in the intensity of headache at 1 hour and the absence of pain at 2 and 4 hours compared with those in the sumatriptan monotherapy group. According to the PPMQ questionnaire, the combined therapy group showed higher treatment satisfaction. Conclusion. The combination of sumatriptan 100 mg and dexketoprofen 25 mg was shown to have some advantage over sumatriptan 100 mg monotherapy in treating migraine attack. The results of the observation program are correlated with those of previous studies. The higher efficiency of combined therapy with triptan + nonsteroidal anti-inflammatory drugs versus that of monotherapy with triptans reflects a variety of pathophysiological processes that accompany a migraine attack, as well as the presence of several targets for pathogenetic therapy.

APA, Harvard, Vancouver, ISO, and other styles

45

Klesov, R. A., V. N. Karkischenko, O. I. Stepanova, and O. V. Baranova. "Comparative Experimental Biomodelling of NSAID-induced Enterocolitis." Journal Biomed 16, no. 1 (2020): 65–81. http://dx.doi.org/10.33647/2074-5982-16-1-65-81.

Full text

Abstract:

Use of non-steroidal anti-inﬂammatory drugs (NSAIDs) is considered to be a factor in the development of gastrointestinal tract (GIT) diseases. Thus, enterocolitis is a frequent complication of NSAIDs. Experimental modelling of GIT diseases in laboratory animals, which describes the origin and mechanism of the corresponding disease in humans with maximal precision, is an urgent problem of modern medicine. This paper presents the results of comparative experimental biomodelling of NSAID-induced enterocolitis in laboratory rats. It was found that the intragastric administration of acetylsalicylic acid resulted mainly in stomach damage. The introduction of dexketoprofen — both orally and intramuscularly — causes erosive and ulcerative lesions of the stomach and intestines. The type of damage showed no correlation with the type of administration. For the ﬁrst time, the results of enterocolitis biomodelling using dexketoprofen are presented.

APA, Harvard, Vancouver, ISO, and other styles

46

Melnik, M. G. "Choice of optimal non-steroidal anti-inflammatory drug from position of cardiologist." Medical alphabet, no. 36 (January 13, 2021): 55–60. http://dx.doi.org/10.33667/2078-5631-2020-36-55-60.

Full text

Abstract:

Non-steroidal anti-inflammatory drugs (NSAIDs) are a large and extremely heterogeneous group of drugs that have a single mechanism of action and therapeutic activity. The article lists their main subgroups by chemical structure and selectivity of action, describes the most typical side effects due to the pharmacodynamic characteristics of drugs, explains the reasons for their formation, and describes the cardiovascular complications they cause. Taking into account the lack of the desired safety of classical NSAIDs for cardiological practice, the possibility of optimizing their tolerance with the help of modern generations of cyclooxygenase inhibitors, namely the dextrorotatory S-enantiomer of ketoprofen – dexketoprofen trometamol (Dexketoprofen-SZ, «Severnaya Zvezda», Russia) was considered. The drug is distinguished by high efficiency and low risk of cardiovascular toxicity, which makes it widely used in symptomatic therapy of cardiac patients.

APA, Harvard, Vancouver, ISO, and other styles

47

Golovacheva, V. A., and A. A. Golovacheva. "Personalized, interdisciplinary approach to the treatment of chronic low back pain: clinical observation." Meditsinskiy sovet = Medical Council, no. 11 (August 8, 2020): 64–69. http://dx.doi.org/10.21518/2079-701x-2020-11-64-69.

Full text

Abstract:

Nonspecific (musculoskeletal) pain is the most common cause of low back pain (LBP). Chronic nonspecific LBP is a particular problem, as it significantly reduces the quality of life and functional activity of the patient. The diagnosis of chronic non-specific LBP is made after exclusion of a specific cause of pain, discogenic radiculopathy and lumbar stenosis. Unfortunately, patients with chronic non-specific LBP are often misdiagnosed, pain chronization factors (“yellow flags”) are ignored and ineffective treatment is prescribed. Clinical observation of a patient with chronic non-specific LBP, who was initially wrongly diagnosed with spinal osteochondrosis and the treatment was ineffective, is presented. A personalized, multidisciplinary approach to treatment allowed the patient to cope with back pain and to return to his previous daily activities. The patient’s treatment plan included non-drug methods of treatment (educational conversation, physical activity, mindfulness, cognitive-behavioural therapy) and rational pharmacotherapy (non-steroidal anti-inflammatory drug, NSAID). Clinical observation showed the efficacy and good tolerability of NSAID - dexketoprofen (in the form of Dexalgin and Dexalgin 25), which was administered in a stepwise scheme for 5 days. According to modern recommendations, NSAIDs are first-line drugs in chronic non-specific LBP. The results of clinical studies on efficacy and safety in back pain of such NSAIDs as dexketoprofen and nimesulide are presented. In case of prolonged exacerbation the possibility of dexketoprofen prescription with subsequent transition to nimesulide is discussed.

APA, Harvard, Vancouver, ISO, and other styles

48

Mauleón, David, Remei Artigas, M. Luisa García, and Germano Carganico. "Preclinical and Clinical Development of Dexketoprofen." Drugs 52, Supplement 5 (1996): 24–46. http://dx.doi.org/10.2165/00003495-199600525-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Asensio, T., M. E. Sanchís, P. Sánchez, J. M. Vega, and J. C. García. "Photocontact dermatitis because of oral dexketoprofen." Contact Dermatitis 58, no. 1 (2007): 59–60. http://dx.doi.org/10.1111/j.1600-0536.2007.01166.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Akdogan, Ali, and Ahmet Eroglu. "Comparison of the Effect of Lidocaine Adding Dexketoprofen and Paracetamol in Intravenous Regional Anesthesia." BioMed Research International 2014 (2014): 1–5. http://dx.doi.org/10.1155/2014/938108.

Full text

Abstract:

Objective.Comparison of dexketoprofen and paracetamol added to the lidocaine in Regional Intravenous Anesthesia in terms of hemodynamic effects, motor and sensorial block onset times, intraoperative VAS values, and analgesia requirements.Method.The files of 73 patients between 18 and 65 years old in the ASA I-II risk group who underwent hand and forearm surgery were analyzed and 60 patients were included in the study. Patients were divided into 3 groups: Group D (n=20), 3 mg/kg 2% lidocaine and 50 mg/2 mL dexketoprofen trometamol; Group P (n=20), 3 mg/kg 2% lidocaine and 3 mg/kg paracetamol; Group K (n=20), 3 mg/kg 2% lidocaine. Demographic data, motor and sensorial block times, heart rate, mean blood pressure, VAS values, and intraoperative and postoperative analgesia requirements were recorded.Results.Sensorial and motor block onset durations of Group K were significantly longer than other groups. Motor block termination duration was found to be significantly longer in Group D than in Group K. VAS values of Group K were found higher than other groups. There was no significant difference in VAS values between Group D and Group P. Analgesia requirement was found to be significantly more in Group K than in Group P. There was no significant difference between the groups in terms of heart rates and mean arterial pressures.Conclusion.We concluded that the addition of 3 mg/kg paracetamol and 50 mg dexketoprofen to lidocaine as adjuvant in Regional Intravenous Anesthesia applied for hand and/or forearm surgery created a significant difference clinically.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!